Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that novel biologic agents from UCB, Centocor/Schering- Plough/Tanabe/Janssen, and Roche/Chugai will play significant roles in ushering in a new phase of growth in the rheumatoid arthritis (RA) drug market.

According to the new Pharmacor report Emerging Rheumatoid Arthritis Therapies, UCB's Cimzia and Centocor/Schering-Plough/Tanabe/Janssen's Golimumab (both TNF-alpha inhibitors), as well as Roche/Chugai's Actemra (an IL-6 inhibitor) will enter an RA drug market that, while fiercely competitive, is burgeoning with untapped opportunity. Additionally, the report finds that, while the early-phase pipeline for RA also includes several novel oral agents, physicians remain cautious about replacing established biologic therapies with novel, orally administered drugs.

Although the emergence of novel biologic agents combined with sales of currently marketed biologics such as Amgen/Wyeth/Takeda's Enbrel and Centocor/Schering-Plough/Tanabe's Remicade will drive near-term market growth, market expansion will slow between 2016 and 2021.

"The rheumatoid arthritis market was dramatically transformed by the emergence of Enbrel and Remicade in the late 1990s as these effective but very expensive biologic agents improved the treatment of moderate to severe disease and drove sales of RA therapies to more than $6 billion annually," said Dancella Fernandes, Ph.D., analyst at Decision Resources. "This market will continue to experience dramatic near-term growth, but market growth will slow between 2016 and 2021 as key market segments reach saturation and third-party payers prevent expansion of biologic therapy into earlier lines of treatment."

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Shake-Up in Omaha Health Plan Front Could Challenge UnitedHealth Group's HMO Market-Leading Position

View Now